COMMUNIQUÉ DE PRESSE publié le 08/05/2024 à 20:40, il y a 4 mois 10 jours enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium Financial Results EnVVeno Medical Corporation SAVVE Trial Venous Disease VenoValve FDA Approval
BRÈVE publiée le 24/04/2024 à 12:20, il y a 4 mois 25 jours Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
BRÈVE publiée le 24/04/2024 à 12:20, il y a 4 mois 25 jours Améliorations cliniques significatives signalées dans l'essai pivot VenoValve d'enVVeno Medical VenoValve Essai Clinique Approbation De La FDA Symposium De Charing Cross Maladie Veineuse
COMMUNIQUÉ DE PRESSE publié le 24/04/2024 à 12:15, il y a 4 mois 25 jours Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRÈVE publiée le 16/04/2024 à 15:05, il y a 5 mois 3 jours EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
BRÈVE publiée le 16/04/2024 à 15:05, il y a 5 mois 3 jours EnVVeno Medical présentera de nouvelles données sur l'efficacité de VenoValve au symposium de Charing Cross Essais Cliniques EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Symposium De Charing Cross
COMMUNIQUÉ DE PRESSE publié le 16/04/2024 à 15:00, il y a 5 mois 3 jours New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRÈVE publiée le 09/04/2024 à 14:50, il y a 5 mois 10 jours EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve® EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
BRÈVE publiée le 09/04/2024 à 14:50, il y a 5 mois 10 jours EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
COMMUNIQUÉ DE PRESSE publié le 09/04/2024 à 14:45, il y a 5 mois 10 jours enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024 FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
Publié le 19/09/2024 à 17:45, il y a 12 minutes Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Publié le 19/09/2024 à 17:45, il y a 12 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:45, il y a 12 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:30, il y a 27 minutes Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Publié le 19/09/2024 à 17:00, il y a 57 minutes Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Publié le 19/09/2024 à 15:45, il y a 2 heures 12 minutes eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Publié le 19/09/2024 à 15:20, il y a 2 heures 37 minutes Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Publié le 19/09/2024 à 15:01, il y a 2 heures 56 minutes ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Publié le 19/09/2024 à 17:45, il y a 12 minutes AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Publié le 19/09/2024 à 17:09, il y a 47 minutes Adler Group S.A. announces the completion of the comprehensive recapitalisation
Publié le 19/09/2024 à 17:00, il y a 56 minutes EQS-Adhoc: SMT Scharf AG: Yankuang new strategic core shareholder
Publié le 19/09/2024 à 15:10, il y a 2 heures 46 minutes Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Publié le 19/09/2024 à 15:08, il y a 2 heures 49 minutes Form 8.3 - The Vanguard Group, Inc.: Ascential plc